VX-147 + Placebo
Phase 2/3Recruiting 0 views this week 0 watching⚡ Active
Interest: 45/100
45
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Proteinuric Kidney Disease
Conditions
Proteinuric Kidney Disease
Trial Timeline
Mar 30, 2022 → Jun 30, 2026
NCT ID
NCT05312879About VX-147 + Placebo
VX-147 + Placebo is a phase 2/3 stage product being developed by Vertex Pharmaceuticals for Proteinuric Kidney Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05312879. Target conditions include Proteinuric Kidney Disease.
What happened to similar drugs?
1 of 1 similar drugs in Proteinuric Kidney Disease were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
15
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05312879 | Phase 2/3 | Recruiting |
Competing Products
4 competing products in Proteinuric Kidney Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aliskiren + Valsartan | Novartis | Approved | 35 |
| Inaxaplin | Vertex Pharmaceuticals | Phase 2 | 42 |
| MZE829 | Maze Therapeutics | Phase 2 | 36 |
| sparsentan + No sparsentan | Travere Therapeutics | Phase 1 | 30 |